ArticleCureus2026
Effects on Glycaemic Control by Continuous Intravenous Regular Insulin With or Without Subcutaneous Glargine Basal Insulin in Patients With Diabetes Following Coronary Artery Bypass Grafting Surgery.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHyperglycemia is common after coronary artery bypass grafting (CABG) among patients with diabetes and has been associated with increased morbidity rates. The conventional strategies involving sliding-scale insulin therapy alone or continuous IV infusion alone are frequently ineffective due to the lack of basal insulin support.
objectivesTo evaluate whether adding subcutaneous glargine to continuous intravenous regular insulin enhances glycaemic control and postoperative outcomes among diabetic patients who undergo CABG.
methodsThis is a prospective observational study carried out among 260 diabetic patients scheduled to undergo elective CABG at the National Institute of Cardiovascular Diseases, Dhaka. The patients were randomly divided into two groups: Group A received continuous IV regular insulin alone, and Group B received continuous IV regular insulin and once-daily subcutaneous glargine. Blood glucose levels were recorded until the second day after the operation. The postoperative complications and outcomes were recorded.
resultsThe mean postoperative blood glucose levels were significantly lower in Group B compared to Group A (mean 9.25 ± 0.84 vs. 12.14 ± 0.77 mmol/L; p <0.001). Group B also had a significantly lower incidence of acute kidney injury (2.3% vs. 23.1%, p <0.001) and sternal wound infection (0.8% vs. 13.1%, p <0.001). The duration of postoperative hospitalisation was less for Group B (9.5 ± 1.3 vs 10.5 ± 1.7 days, p <0.001). Mortality rates were equally matched by the two groups.
conclusionThe study concludes that combining subcutaneous glargine with continuous intravenous infusion of insulin achieves optimal glycaemic control following surgery and reduces morbidity amongst diabetic CABG patients when compared with intravenous insulin alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.